Phase II Clinical Trials CROs in France

Mid-size global CRO under ALTEN Group formed by integrating Cmed and Larix, with deep oncology, rare disease, and cell/gene therapy clinical trial expertise across the US and Europe.

French CRO providing Phase I-III clinical development services with particular expertise in metabolic disease, endocrinology, and cardiovascular trials across Europe.

French CRO providing Phase I-III clinical trial management and monitoring services across France and Western Europe, with expertise in rare disease and orphan drug development.

Nantes-based French CRO specialising in CNS, sleep medicine, and neuroscience clinical trials with proprietary EEG/PSG expertise and Phase I-II clinical pharmacology capabilities.

Paris-based European CRO providing clinical operations, pharmacovigilance, and regulatory affairs services across 40+ countries with particular strength in oncology and rare disease.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

French clinical-stage gene therapy company and CRO specializing in CNS gene therapy development, providing clinical trial management for rare neurological diseases.

French mid-size CRO specialising in Phase I-III clinical trials, biostatistics, and regulatory affairs with offices in Paris and North Africa.